Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 2/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CPB1 | P15086 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4804145 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9APOLBFKBP1A | |
| SCHEMBL4804132 | 1.00 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9APOLBFKBP1A | |
| SCHEMBL7819386 | 0.94 | POLB (0.50) | SMN1; SMN2NPC1RAB9APOLBFKBP1A | |
| SCHEMBL8525578 | 0.94 | POLB (0.50) | SMN1; SMN2NPC1RAB9APOLBFKBP1A | |
| SCHEMBL8482453 | 0.94 | POLB (0.50) | SMN1; SMN2NPC1RAB9APOLBFKBP1A | |
| SCHEMBL4808093 | 0.94 | POLB (0.50) | SMN1; SMN2NPC1RAB9APOLBFKBP1A | |
| SCHEMBL8524021 | 0.94 | POLB (0.50) | SMN1; SMN2NPC1RAB9APOLBFKBP1A | |
| SCHEMBL8481499 | 0.89 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9APOLBNPSR1 | |
| SCHEMBL8477065 | 0.89 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9APOLBNPSR1 | |
| SCHEMBL8479641 | 0.89 | SMN1; SMN2 (0.57) | SMN1; SMN2NPC1RAB9APOLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170145032-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2017-05-25 | — | — | US | disclosed |
| US-20170145032-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2017-05-25 | — | — | US | disclosed |
| US-9624243-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-9624243-B2 | Heterocyclic compounds and methods of their use | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-20140378430-A1 | Heterocyclic Compounds and Methods of Their Use | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-12-25 | — | — | US | disclosed |
| US-20140378430-A1 | Heterocyclic Compounds and Methods of Their Use | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2014-12-25 | — | — | US | disclosed |
| WO-2013102242-A1 | HETEROCYCLIC COMPOUNDS AND METHODS FOR THEIR USE | SPINIFEX PHARMACEUTICALS PTY LTD (AU) | 2013-07-11 | — | — | WO | disclosed |
| US-7425633-B2 | Pyrrolidine compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2008-09-16 | — | — | US | disclosed |
| US-20070082932-A1 | Pyrrolidine compounds | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378430-A1 | Heterocyclic Compounds and Methods of Their Use | AGTR2, AGTR1, BDKRB2 | SMN1; SMN2 958/4885NPC1 2943/4885RAB9A 1239/4885 |
| US-20170145032-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF THEIR USE | AGTR2, AGTR1, BDKRB2 | SMN1; SMN2 958/4885NPC1 2943/4885RAB9A 1239/4885 |
| US-20070082932-A1 | Pyrrolidine compounds | DPP4, DPP7, DPP9 | SMN1; SMN2 4437/4885NPC1 3371/4885RAB9A 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.